Compare HITI & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HITI | BIOA |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.6M | 255.6M |
| IPO Year | 2021 | 2024 |
| Metric | HITI | BIOA |
|---|---|---|
| Price | $2.66 | $5.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 10 |
| Target Price | $4.67 | ★ $32.56 |
| AVG Volume (30 Days) | 530.7K | ★ 830.4K |
| Earning Date | 09-14-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 66.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,995,000.00 |
| Revenue This Year | $27.52 | N/A |
| Revenue Next Year | $10.52 | $97.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.02 | $4.81 |
| 52 Week High | $3.50 | $25.96 |
| Indicator | HITI | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 51.52 | 31.30 |
| Support Level | $2.47 | N/A |
| Resistance Level | $2.73 | $8.53 |
| Average True Range (ATR) | 0.09 | 0.37 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 50.91 | 35.92 |
High Tide Inc is a downstream-focused retailer of cannabis products, distributor, and seller of smoking accessories and cannabis lifestyle products. It is a vertically integrated company in the Canadian cannabis market with various brands in its portfolio such as Canna Cabana, Fastendr, Queen of Bud, Grasscity, Daily High Club, and others. The company's reportable operating segments are: Bricks and mortar, which generates maximum revenue, and E-commerce. Geographically, it derives maximum revenue from its business in Canada, followed by the United States of America, and other international markets.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.